TUCSON, Ariz., Jan. 12, 2022 /PRNewswire/ -- Accelerate
Diagnostics, Inc. (Nasdaq: AXDX) announced today that it was
honored as a recipient of China's
Suzhou Industrial Park's (SIP) 15th Science and
Technology Leaders Innovation Award for the Company's Accelerate
Pheno® System.
In order to enhance and promote continuous growth of its
world-class high-tech Industrial Park, and to attract high-tech
innovation and entrepreneurial leaders (teams) to the SIP, Suzhou,
the Science and Technology Leaders Innovation and Entrepreneurship
Award competition is conducted twice a year. Every competition
attracts hundreds of applicants for this prestigious award. In a
public announcement on December 29,
2021, released by the SIP Science and Technology Innovation
Committee, the Accelerate Pheno System, an innovative infectious
disease etiological agents rapid identification and antibiotics
susceptibility testing automated platform, won the "Leading
Entrepreneurial Talent – Incubation" category. The Accelerate
Pheno System was recognized for its potential to reduce morbidity
and mortality associated with bacteremia, as well as reducing the
burden of antimicrobial resistance, by providing rapid
identification and antimicrobial susceptibility test results days
earlier than current diagnostic methods.
Accelerate Diagnostics plans to continue its strategy to
localize and access the Chinese market with its market leading
Accelerate Pheno System to provide a much needed rapid diagnostic
tool to fight antimicrobial resistance in China. The award
brings further recognition to the Accelerate Pheno System and will
help to defray near-term costs to continue commercialization
efforts in China.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in
vitro diagnostics company dedicated to providing solutions
for the global challenges of antibiotic resistance and sepsis. The
Accelerate Pheno® system and Accelerate
PhenoTest® BC kit combine several technologies
aimed at reducing the time clinicians must wait to determine the
most optimal antibiotic therapy for deadly infections. The FDA
cleared system and kit fully automate the sample preparation steps
to report phenotypic antibiotic susceptibility results in
approximately 7 hours direct from positive blood cultures. Recent
external studies indicate the solution offers results 1-2 days
faster than existing methods, enabling clinicians to optimize
antibiotic selection and dosage specific to the individual patient
days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and
"ACCELERATE PHENO TEST" and diamond shaped logos and marks are
trademarks or registered trademarks of Accelerate Diagnostics,
Inc.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as any plans we may have to enter the China market commercially. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Information about the risks
and uncertainties faced by Accelerate Diagnostics is contained in
the section captioned "Risk Factors" in the company's most recent
Annual Report on Form 10-K, filed with the Securities and Exchange
Commission on March 2, 2021, and in any other reports that the
Company files with the Securities and Exchange Commission. The
Company's forward-looking statements could be affected by general
industry and market conditions. Except as required by federal
securities laws, the Company undertakes no obligation to update or
revise these forward-looking statements to reflect new events,
uncertainties or other contingencies.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-wins-suzhou-innovation-award-to-support-continued-china-commercialization-efforts-301458961.html
SOURCE Accelerate Diagnostics, Inc.